Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets. In November 2014, the Company announced a change in organizational structure designed to serve its customers. Its life sciences business, excluding the nucleic acid solutions division, together with the chemical analysis business combined to form a new segment called life sciences and applied markets business. Its diagnostics and genomics businesses combined with the nucleic acid solutions division from its life sciences business and became the diagnostics and genomics segment. Finally, the Agilent CrossLab segment was formed from the services and consumables businesses previously part of the life sciences and chemical analysis businesses. The Company's life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The diagnostics and genomics business is comprised of three areas of activity providing solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. In addition it conducts centralized order fulfillment and supply chain operations for businesses through the order fulfillment and supply chain organization (OFS). OFS provides resources for manufacturing, engineering and strategic sourcing to the Company's respective businesses. The life sciences and applied markets business focuses on The Pharmaceutical, Biotechnology, CRO & CMO Market; The Life Science Research Market; The Chemical & Energy Market; The Environmental & Forensics Market; and the Food Market. Its products fall into nine areas of work: liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, software and informatics, lab automation and robotics, automated electrophoresis and microfluidics, vacuum technology and nuclear magnetic resonance systems. The diagnostics and genomics business includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid contract manufacturing businesses. The segment focuses on The Diagnostics and Clinical Market. The products under the segment fall into six areas of work: pathology products, specific proteins and flow reagents, target enrichment, cytogenetic research solutions and microarrays, PCR and qPCR instrumentation and molecular biology reagents and nucleic acid solutions. The Agilent CrossLab segment focuses on The Pharmaceutical, Biotechnology, CRO & CMO Market; The Life Science Research Market; The Chemical & Energy Market; The Environmental & Forensics Market; The Food Market; and The Diagnostics and Clinical Market. The Company sells its products through direct sales, but it also utilizes distributors, resellers, manufacturer's representatives and electronic commerce. Its research and development and manufacturing sites are in California, Colorado, Delaware and Texas in the U.S. and in Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.